Preliminary clinical experience on the efficacy and feasibility of a new combination regimen consisting of pixantrone (Pix), etoposide, and bendamustine with or without the addition of rituximab in patients with relapsed/refractory aggressive non-Hodgkin lymphomas (aNHL)
Published in 2015 by
F. d'Amore,
J. Jorgensen,
I. Sillesen,
E. Segel,
H. Bentzen,
M. Thorsgaard,
E. J. Pulczinsky,
B. B. Pedersen,
D. Gillstroem,
M. Clausen,
P. Kamper,
T. Silkjaer,
L. Gormsen,
Sirpa Marianne Leppä 
,
H. E. Toldbod
and other authors.
,
H. E. Toldbod
and other authors.
